<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Parkinson’s disease repositories with genetic data.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Repository</th>
    <th>Participant types</th>
    <th>Genetic data screened</th>
    <th>Other type of data</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>HBS (USA, Canada)
     <sup>
      <xref ref-type="bibr" rid="CR18">18</xref>
     </sup>
    </td>
    <td>PD and HC</td>
    <td>Targeted sequencing or Asn370Ser, Glu326Lys, Thr369Met genotyping</td>
    <td>Motor and nonmotor assessments, biospecimen data, neuroimaging data</td>
   </tr>
   <tr>
    <td>DIGPD (France)
     <sup>
      <xref ref-type="bibr" rid="CR10">10</xref>
     </sup>
    </td>
    <td>PD and HC</td>
    <td>Sanger sequencing</td>
    <td>Motor and nonmotor assessments</td>
   </tr>
   <tr>
    <td>CamPaIGN (UK)
     <sup>
      <xref ref-type="bibr" rid="CR19">19</xref>
     </sup>
    </td>
    <td>PD and subjects diagnosed with other causes of parkinsonism/tremor</td>
    <td>Sanger sequencing; SNP genotype</td>
    <td>Motor and nonmotor assessments</td>
   </tr>
   <tr>
    <td>PROPARK (Netherlands)
     <sup>
      <xref ref-type="bibr" rid="CR20">20</xref>
     </sup>
    </td>
    <td>PD</td>
    <td>Targeted sequencing or whole exome sequencing</td>
    <td>Motor and nonmotor assessments</td>
   </tr>
   <tr>
    <td>LABS-PD (USA, Canada)
     <sup>
      <xref ref-type="bibr" rid="CR21">21</xref>
     </sup>
    </td>
    <td>PD and HC</td>
    <td>Targeted sequencing</td>
    <td>Motor and nonmotor assessments, biomarkers, imaging data</td>
   </tr>
   <tr>
    <td>PICNICS (UK)
     <sup>
      <xref ref-type="bibr" rid="CR22">22</xref>
     </sup>
    </td>
    <td>PD</td>
    <td>Sanger sequencing</td>
    <td>Motor and nonmotor assessments</td>
   </tr>
   <tr>
    <td>DATATOP (USA, Canada)
     <sup>
      <xref ref-type="bibr" rid="CR23">23</xref>
     </sup>
    </td>
    <td>PD</td>
    <td>Targeted sequencing</td>
    <td>Motor and nonmotor assessments</td>
   </tr>
   <tr>
    <td>PDBP
     <sup>
      <xref ref-type="bibr" rid="CR24">24</xref>
     </sup>
    </td>
    <td>PD and HC</td>
    <td>NeuroX genotyping</td>
    <td>Motor and nonmotor assessments</td>
   </tr>
   <tr>
    <td>Penn-Udall (USA)</td>
    <td>PD</td>
    <td>Targeted sequencing</td>
    <td>Motor and nonmotor assessments</td>
   </tr>
   <tr>
    <td>PPMI (USA, Europe)
     <sup>
      <xref ref-type="bibr" rid="CR25">25</xref>
     </sup>
    </td>
    <td>PD, SWEED, and HC</td>
    <td>Whole exome sequence</td>
    <td>Motor and nonmotor assessments, CSF biomarkers, neuroimaging data</td>
   </tr>
   <tr>
    <td>BioFIND (USA)
     <sup>
      <xref ref-type="bibr" rid="CR26">26</xref>
     </sup>
    </td>
    <td>PD and HC</td>
    <td>Whole genomic sequence of the GBA1 gene</td>
    <td>Motor and nonmotor assessments, biospecimen data</td>
   </tr>
   <tr>
    <td>IPDGC (worldwide)
     <sup>
      <xref ref-type="bibr" rid="CR30">30</xref>
     </sup>
    </td>
    <td>PD and HC</td>
    <td>NeuroX genotyping</td>
    <td>Not specified</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>CamPaIGN</italic> Cambridgeshire Parkinson’s incidence from General Practitioner to Neurologist, 
   <italic>DIGPD</italic> Drug Interaction with Genes in Parkinson’s Disease, 
   <italic>EMBL-EMI</italic> The European Bioinformatics Institute, 
   <italic>HBS</italic> Harvard Biomarkers Study, 
   <italic>IPDGC</italic> International Parkinson’s Disease Genomics Consortium, 
   <italic>LABS-PD</italic> Longitudinal and Biomarker Study in Parkinson’s disease, 
   <italic>NCBI</italic> The National Center for Biotechnology Information, 
   <italic>PD</italic> Parkinson’s disease, 
   <italic>PDPB</italic> Parkinson’s Disease Biomarkers Program, 
   <italic>Penn-Udall</italic> Morris K Udall Parkinson’s Disease Research Center of Excellence cohort, 
   <italic>PICNICS</italic> Parkinsonism: Incidence, Cognition and Non–motor heterogeneity in Cambridgeshire, 
   <italic>PPMI</italic> Parkinson’s Progression Marker Initiative, 
   <italic>PreCEPT</italic> Parkinson Research Examination of CEP–1347 Trial, 
   <italic>PROPARK</italic> PROFIling PARKinson’s disease, 
   <italic>SWEDD</italic> scans without evidence of dopaminergic deficit.
  </p>
 </table-wrap-foot>
</table-wrap>
